Author:
Kostopoulos Ioannis,Arapantoni-Dadioti Petroula,Gogas Helen,Papadopoulos Savvas,Malamou-Mitsi Vasiliki,Scopa Chrisoula D.,Markaki Sofia,Karagianni Evangelia,Kyriakou Vasiliki,Margariti Anastasia,Kyrkou Elisavet,Pavlakis Kitty,Zaramboukas Thomas,Skordalaki Anna,Bourli Antonia,Markopoulos Christos,Pectasides Dimitrios,Dimopoulos Meletios A.,Skarlos Dimosthenis,Fountzilas George
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Early Breast Cancer Trialists Collaborative Group: 1998 Polychemotherapy for early breast cancer: an overview of the randomized trials Lancet 352: 930–942
2. Hayes DF, Bast RC, Desch CE, Fritsche H Jr., Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ, 1996 Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers J Natl Cancer Inst 88: 1456–1466
3. Gusterson BA, 1995 The changing role of pathologist in the prediction of tumor behaviour and response to treatment it. In: Dickson RB, Lippman ME, (eds.) Drug and Hormonal Resistance in Breast Cancer. Ellis Horwood, New York, p. 39–53
4. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T, 1986 The product of the human c-erbB2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232: 1644–1646
5. Ross JS, Fletcher JA, 1999 HER-2/neu (c-erbB2) gene and protein in breast cancer Am J Clin Pathol 112: S53–S67
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献